Deeper insights into long-term survival heterogeneity of pancreatic ductal adenocarcinoma (PDAC) patients using integrative individual- and group-level transcriptome network analyses.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
30 06 2022
Historique:
received: 09 07 2021
accepted: 09 06 2022
entrez: 30 6 2022
pubmed: 1 7 2022
medline: 6 7 2022
Statut: epublish

Résumé

Pancreatic ductal adenocarcinoma (PDAC) is categorized as the leading cause of cancer mortality worldwide. However, its predictive markers for long-term survival are not well known. It is interesting to delineate individual-specific perturbed genes when comparing long-term (LT) and short-term (ST) PDAC survivors and integrate individual- and group-based transcriptome profiling. Using a discovery cohort of 19 PDAC patients from CHU-Liège (Belgium), we first performed differential gene expression analysis comparing LT to ST survivor. Second, we adopted systems biology approaches to obtain clinically relevant gene modules. Third, we created individual-specific perturbation profiles. Furthermore, we used Degree-Aware disease gene prioritizing (DADA) method to develop PDAC disease modules; Network-based Integration of Multi-omics Data (NetICS) to integrate group-based and individual-specific perturbed genes in relation to PDAC LT survival. We identified 173 differentially expressed genes (DEGs) in ST and LT survivors and five modules (including 38 DEGs) showing associations to clinical traits. Validation of DEGs in the molecular lab suggested a role of REG4 and TSPAN8 in PDAC survival. Via NetICS and DADA, we identified various known oncogenes such as CUL1 and TGFB1. Our proposed analytic workflow shows the advantages of combining clinical and omics data as well as individual- and group-level transcriptome profiling.

Identifiants

pubmed: 35773268
doi: 10.1038/s41598-022-14592-1
pii: 10.1038/s41598-022-14592-1
pmc: PMC9247075
doi:

Substances chimiques

Biomarkers, Tumor 0
TSPAN8 protein, human 0
Tetraspanins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11027

Informations de copyright

© 2022. The Author(s).

Références

Hidalgo, M. et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology 15, 8–18 (2015).
pubmed: 25547205 doi: 10.1016/j.pan.2014.10.001
Valle, S., Martin-Hijano, L., Alcalá, S., Alonso-Nocelo, M. & Sainz, B. Jr. The ever-evolving concept of the cancer stem cell in pancreatic cancer. Cancers 10, 33 (2018).
pmcid: 5836065 doi: 10.3390/cancers10020033
Garrido-Laguna, I. & Hidalgo, M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat. Rev. Clin. Oncol. 12, 319–334 (2015).
pubmed: 25824606 doi: 10.1038/nrclinonc.2015.53
Nevala-Plagemann, C., Hidalgo, M. & Garrido-Laguna, I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat. Rev. Clin. Oncol. 17, 108–123 (2020).
pubmed: 31705130 doi: 10.1038/s41571-019-0281-6
Olive, K. P. et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457–1461 (2009).
pubmed: 19460966 pmcid: 2998180 doi: 10.1126/science.1171362
Barabási, A.-L., Gulbahce, N. & Loscalzo, J. Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12, 56 (2011).
pubmed: 21164525 pmcid: 3140052 doi: 10.1038/nrg2918
Erten, S., Bebek, G., Ewing, R. M. & Koyutürk, M. DADA: degree-aware algorithms for network-based disease gene prioritization. BioData Min. 4, 19–19 (2011).
pubmed: 21699738 pmcid: 3143097 doi: 10.1186/1756-0381-4-19
Kaiser, M. H. & Ellenberg, S. S. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch. Surg. 120, 899–903 (1985).
doi: 10.1001/archsurg.1985.01390320023003
Riediger, H. et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J. Gastrointest. Surg. 13, 1337 (2009).
pubmed: 19418101 doi: 10.1007/s11605-009-0919-2
Osipov, A. et al. Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy. J. Gastrointest. Oncol. 7, 239 (2016).
pubmed: 27034792 pmcid: 4783734
Schlitter, A. M. et al. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes. Sci. Rep. 7, 41064 (2017).
pubmed: 28145465 pmcid: 5286512 doi: 10.1038/srep41064
Liu, B. et al. Identification of prognostic biomarkers by combined mRNA and miRNA expression microarray analysis in pancreatic cancer. Transl. Oncol. 11, 700–714 (2018).
pubmed: 29631214 pmcid: 6154866 doi: 10.1016/j.tranon.2018.03.003
Xiong, G. et al. MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. J. Exp. Clin. Cancer Res. 37, 76 (2018).
pubmed: 29615098 pmcid: 5883523 doi: 10.1186/s13046-018-0739-x
Collisson, E. A. & Maitra, A. Pancreatic cancer genomics 2.0: profiling metastases. Cancer Cell 31, 309–310 (2017).
pubmed: 28292434 doi: 10.1016/j.ccell.2017.02.014
Roychowdhury, S. & Chinnaiyan, A. M. Translating cancer genomes and transcriptomes for precision oncology. CA Cancer J. Clin. 66, 75–88 (2016).
pubmed: 26528881 doi: 10.3322/caac.21329
Chaika, N. V. et al. Differential expression of metabolic genes in tumor and stromal components of primary and metastatic loci in pancreatic adenocarcinoma. PLoS ONE 7, e32996 (2012).
pubmed: 22412968 pmcid: 3296773 doi: 10.1371/journal.pone.0032996
Mao, Y. et al. RNA sequencing analyses reveal novel differentially expressed genes and pathways in pancreatic cancer. Oncotarget 8, 42537 (2017).
pubmed: 28418924 pmcid: 5522086 doi: 10.18632/oncotarget.16451
Newhook, T. E. et al. A thirteen-gene expression signature predicts survival of patients with pancreatic cancer and identifies new genes of interest. PLoS ONE 9, e105631 (2014).
pubmed: 25180633 pmcid: 4152146 doi: 10.1371/journal.pone.0105631
Rao, M. et al. PO-277 single-cell RNA-seq analysis of human pancreatic ductal adenocarcinoma. ESMO Open 3, A336 (2018).
doi: 10.1136/esmoopen-2018-EACR25.791
Duconseil, P. et al. Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma. Am. J. Pathol. 185, 1022–1032 (2015).
pubmed: 25765988 doi: 10.1016/j.ajpath.2014.11.029
Stark, A. P. et al. Long-term survival in patients with pancreatic ductal adenocarcinoma. Surgery 159, 1520–1527 (2016).
pubmed: 26847803 doi: 10.1016/j.surg.2015.12.024
Chen, R. et al. Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma. Cancer Biol. Therapy 13, 899–907 (2012).
doi: 10.4161/cbt.20842
Zhao, L., Zhao, H. & Yan, H. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes. BMC Cancer 18, 603 (2018).
pubmed: 29843660 pmcid: 5975421 doi: 10.1186/s12885-018-4546-8
Menche, J. et al. Integrating personalized gene expression profiles into predictive disease-associated gene pools. NPJ Syst. Biol. Appl. 3, 10 (2017).
pubmed: 28649437 pmcid: 5445628 doi: 10.1038/s41540-017-0009-0
Puleo, F. et al. Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features. Gastroenterology 155, 1999–2013 (2018).
pubmed: 30165049 doi: 10.1053/j.gastro.2018.08.033
Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47 (2016).
pubmed: 26909576 doi: 10.1038/nature16965
Peran, I., Madhavan, S., Byers, S. W. & McCoy, M. D. Curation of the pancreatic ductal adenocarcinoma subset of the cancer genome Atlas is essential for accurate conclusions about survival related molecular mechanisms. Clin. Cancer Res. 24, 3813–3819 (2018).
pubmed: 29739787 doi: 10.1158/1078-0432.CCR-18-0290
Presson, A. P. et al. Protein expression based multimarker analysis of breast cancer samples. BMC Cancer 11, 230 (2011).
pubmed: 21651811 pmcid: 3142534 doi: 10.1186/1471-2407-11-230
Wirapati, P. et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 10, R65 (2008).
pubmed: 18662380 pmcid: 2575538 doi: 10.1186/bcr2124
Wang, L. et al. Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res. 69, 9490–9497 (2009).
pubmed: 19996289 pmcid: 2795036 doi: 10.1158/0008-5472.CAN-09-2183
Giulietti, M., Occhipinti, G., Principato, G. & Piva, F. Weighted gene co-expression network analysis reveals key genes involved in pancreatic ductal adenocarcinoma development. Cell. Oncol. 39, 379–388 (2016).
doi: 10.1007/s13402-016-0283-7
Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 9, 559 (2008).
doi: 10.1186/1471-2105-9-559
Sharma, A. et al. Integration of molecular interactome and targeted interaction analysis to identify a COPD disease network module. Sci. Rep. 8, 14439 (2018).
pubmed: 30262855 pmcid: 6160419 doi: 10.1038/s41598-018-32173-z
Piñero, J. et al. The DisGeNET knowledge platform for disease genomics. Nucl. Acids Res. 48, D845–D855 (2019).
pmcid: 7145631
Bailey, M. H. et al. Comprehensive characterization of cancer driver genes and mutations. Cell 173, 371–385 (2018).
pubmed: 29625053 pmcid: 6029450 doi: 10.1016/j.cell.2018.02.060
Kim, J. H., Byun, S. J., Park, S. G., Oh, Y. K. & Baek, S. K. Interval between surgery and radiation therapy is an important prognostic factor in treatment of rectal cancer. Cancer Res. Treat. 44, 187–194 (2012).
pubmed: 23091445 pmcid: 3467422 doi: 10.4143/crt.2012.44.3.187
Haider, S. et al. A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. Genome Med. 6, 105 (2014).
pubmed: 25587357 pmcid: 4293116 doi: 10.1186/s13073-014-0105-3
Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399 (2012).
pubmed: 23103869 pmcid: 3530898 doi: 10.1038/nature11547
Zhu, T. et al. Genome-scale analysis identifies GJB2 and ERO1LB as prognosis markers in patients with pancreatic cancer. Oncotarget 8, 21281 (2017).
pubmed: 28177904 pmcid: 5400583 doi: 10.18632/oncotarget.15068
Raman, P., Maddipati, R., Lim, K. H. & Tozeren, A. Pancreatic cancer survival analysis defines a signature that predicts outcome. PLoS ONE 13, e0201751 (2018).
pubmed: 30092011 pmcid: 6084949 doi: 10.1371/journal.pone.0201751
Osaki, M., Oshimura, M. & Ito, H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9, 667–676 (2004).
pubmed: 15505410 doi: 10.1023/B:APPT.0000045801.15585.dd
Glazer, E. S., Welsh, E., Pimiento, J. M., Teer, J. K. & Malafa, M. P. TGFβ1 overexpression is associated with improved survival and low tumor cell proliferation in patients with early-stage pancreatic ductal adenocarcinoma. Oncotarget 8, 999 (2017).
pubmed: 27895310 doi: 10.18632/oncotarget.13533
Paniccia, A., Merkow, J., Edil, B. H. & Zhu, Y. Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials. Chin. J. Cancer Res. 27, 376–391 (2015).
pubmed: 26361407 pmcid: 4560736
Fan, Z. et al. Critical role of KRAS mutation in pancreatic ductal adenocarcinoma. Transl. Cancer Res. 7, 1728–1736 (2018).
doi: 10.21037/tcr.2018.10.19
Altieri, F. et al. Epigenetic alterations of gastrokine 1 gene expression in gastric cancer. Oncotarget 8, 16899 (2017).
pubmed: 28129645 pmcid: 5370009 doi: 10.18632/oncotarget.14817
Yao, H. et al. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma. Cancer Biomark. 17, 397–404 (2016).
pubmed: 27689616 doi: 10.3233/CBM-160655
Takehara, A. et al. Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4. Cancer Sci. 97, 1191–1197 (2006).
pubmed: 16918991 doi: 10.1111/j.1349-7006.2006.00297.x
Lin, X. et al. TSPAN8 serves as a prognostic marker involving Akt/MAPK pathway in nasopharyngeal carcinoma. Ann. Transl. Med. 7, 18 (2019).
doi: 10.21037/atm.2019.08.02
Halbrook, C. J. & Lyssiotis, C. A. Employing metabolism to improve the diagnosis and treatment of pancreatic cancer. Cancer Cell 31, 5–19 (2017).
pubmed: 28073003 doi: 10.1016/j.ccell.2016.12.006
Shurin, M. R. Immunological targets for cancer therapy: new recognition. ImmunoTargets Therapy 7, 83 (2018).
pubmed: 30538966 pmcid: 6254540 doi: 10.2147/ITT.S191821
Oldham, M. C., Horvath, S. & Geschwind, D. H. Conservation and evolution of gene coexpression networks in human and chimpanzee brains. Proc. Natl. Acad. Sci. 103, 17973–17978 (2006).
pubmed: 17101986 pmcid: 1693857 doi: 10.1073/pnas.0605938103
Wang, J. et al. Single-cell co-expression analysis reveals distinct functional modules, co-regulation mechanisms and clinical outcomes. PLoS Comput. Biol. 12, e1004892 (2016).
pubmed: 27100869 pmcid: 4839722 doi: 10.1371/journal.pcbi.1004892
Ballouz, S., Verleyen, W. & Gillis, J. Guidance for RNA-seq co-expression network construction and analysis: safety in numbers. Bioinformatics 31, 2123–2130 (2015).
pubmed: 25717192 doi: 10.1093/bioinformatics/btv118
Hur, C. et al. Early pancreatic ductal adenocarcinoma survival is dependent on size: positive implications for future targeted screening. Pancreas 45, 1062 (2016).
pubmed: 26692444 pmcid: 4912943 doi: 10.1097/MPA.0000000000000587
Marchegiani, G. et al. Does the surgical waiting list affect pathological and survival outcome in resectable pancreatic ductal adenocarcinoma?. HPB 20, 411–417 (2018).
pubmed: 29191689 doi: 10.1016/j.hpb.2017.10.017
Zhou, L. et al. Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma. Sci. Transl. Med. 10, eaat3487 (2018).
pubmed: 30355799 pmcid: 6752716 doi: 10.1126/scitranslmed.aat3487
Stone, B. et al. Can gene expression profiling identify pancreatic ductal adenocarcinoma patients with short or long-term prognosis?. J. Pancreas 19, 118–125 (2018).
Dal Molin, M. & Wood, L. D. Very long-term survival in pancreatic cancer. Aging (Albany NY) 7, 360 (2015).
doi: 10.18632/aging.100771
Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor-and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47, 1168 (2015).
pubmed: 26343385 pmcid: 4912058 doi: 10.1038/ng.3398
Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495 (2015).
pubmed: 25719666 pmcid: 4523082 doi: 10.1038/nature14169
Marino, F. Z. et al. Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications. Int. J. Med. Sci. 16, 981 (2019).
doi: 10.7150/ijms.34739
Zhou, H. et al. Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer. Nat. Commun. 12, 1–11 (2021).
doi: 10.1038/s41467-021-25787-x
Decaup, E., Rochotte, J., Pyronnet, S., Bousquet, C. & Jean, C. Focal adhesion kinase: a promising therapeutic target in pancreatic adenocarcinoma. Clin. Res. Hepatol. Gastroenterol. 41, 246–248 (2017).
pubmed: 27939096 doi: 10.1016/j.clinre.2016.10.010
Weniger, M., Honselmann, K. & Liss, A. The extracellular matrix and pancreatic cancer: a complex relationship. Cancers 10, 316 (2018).
pmcid: 6162452 doi: 10.3390/cancers10090316
McCleary-Wheeler, A. L., McWilliams, R. & Fernandez-Zapico, M. E. Aberrant signaling pathways in pancreatic cancer: a two compartment view. Mol. Carcinog. 51, 25–39 (2012).
pubmed: 22162229 pmcid: 3253704 doi: 10.1002/mc.20827
Le Large, T. Y. S. et al. Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies. Semin. Cancer Biol. 44, 153–169 (2017).
pubmed: 28366542 doi: 10.1016/j.semcancer.2017.03.008
Birnbaum, D. J. et al. A 25-gene classifier predicts overall survival in resectable pancreatic cancer. BMC Med. 15, 170 (2017).
pubmed: 28927421 pmcid: 5606023 doi: 10.1186/s12916-017-0936-z
Isik, Z., Baldow, C., Cannistraci, C. V. & Schroeder, M. Drug target prioritization by perturbed gene expression and network information. Sci. Rep. 5, 17417 (2015).
pubmed: 26615774 pmcid: 4663505 doi: 10.1038/srep17417
Mullen, J., Cockell, S. J., Woollard, P. & Wipat, A. An integrated data driven approach to drug repositioning using gene-disease associations. PLoS ONE 11, e0155811 (2016).
pubmed: 27196054 pmcid: 4873016 doi: 10.1371/journal.pone.0155811
Xie, C.-M., Wei, W. & Sun, Y. Role of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases in skin cancer. J. Genet. Genom. 40, 97–106 (2013).
doi: 10.1016/j.jgg.2013.02.001
Vallejo, A. et al. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Nat. Commun. 8, 14294 (2017).
pubmed: 28220783 pmcid: 5321758 doi: 10.1038/ncomms14294
Awasthi, N. et al. Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer. J. Cell. Mol. Med. 23, 3878–3887 (2019).
pubmed: 30941918 pmcid: 6533474 doi: 10.1111/jcmm.14242
Rajurkar, M. et al. The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis. Proc. Natl. Acad. Sci. 109, E1038–E1047 (2012).
pubmed: 22493246 pmcid: 3340052 doi: 10.1073/pnas.1114168109
Danilova, L. et al. Programmed cell death ligand-1 (PD-L1) and CD8 expression profiling identify an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival. Cancer Immunol. Res. 7, 886–895 (2019).
pubmed: 31043417 pmcid: 6548624 doi: 10.1158/2326-6066.CIR-18-0822
Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120 (2014).
pubmed: 24695404 pmcid: 4103590 doi: 10.1093/bioinformatics/btu170
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
pubmed: 23104886 doi: 10.1093/bioinformatics/bts635
Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015).
pubmed: 25260700 doi: 10.1093/bioinformatics/btu638
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281 pmcid: 4302049 doi: 10.1186/s13059-014-0550-8
Zhang, W., Liu, S., Zhan, H., Yan, Z. & Zhang, G. Transcriptome sequencing identifies key pathways and genes involved in gastric adenocarcinoma. Mol. Med. Rep. 18, 3673–3682 (2018).
pubmed: 30106143 pmcid: 6131596
Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics J. Integ. Biol. 16, 284–287 (2012).
doi: 10.1089/omi.2011.0118
Marchler-Bauer, A. et al. CDD/SPARCLE: functional classification of proteins via subfamily domain architectures. Nucl. Acids Res. 45, D200–D203 (2006).
doi: 10.1093/nar/gkw1129
Therneau T. A package for survival analysis in S. (R package version 2.38 2015)
Langfelder, P., Zhang, B. & Horvath, S. Defining clusters from a hierarchical cluster tree: the dynamic tree cut package for R. Bioinformatics 24, 719–720 (2008).
pubmed: 18024473 doi: 10.1093/bioinformatics/btm563
Liu, R., Cheng, Y., Yu, J., Lv, Q.-L. & Zhou, H.-H. Identification and validation of gene module associated with lung cancer through coexpression network analysis. Gene 563, 56–62 (2015).
pubmed: 25752287 doi: 10.1016/j.gene.2015.03.008
Bindea, G. et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25, 1091–1093 (2009).
pubmed: 19237447 pmcid: 2666812 doi: 10.1093/bioinformatics/btp101
Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
pubmed: 14597658 pmcid: 403769 doi: 10.1101/gr.1239303
Anderson, M. J. Permutation tests for univariate or multivariate analysis of variance and regression. Can. J. Fish. Aquat. Sci. 58, 626–639 (2001).
doi: 10.1139/f01-004
Chen, J., Bardes, E. E., Aronow, B. J. & Jegga, A. G. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucl. Acids Res. 37, W305–W311 (2009).
pubmed: 19465376 pmcid: 2703978 doi: 10.1093/nar/gkp427
Galili, T. dendextend: an R package for visualizing, adjusting and comparing trees of hierarchical clustering. Bioinformatics 31, 3718–3720 (2015).
pubmed: 26209431 pmcid: 4817050 doi: 10.1093/bioinformatics/btv428
De Troyer E, Otava M. RcmdrPlugin. BiclustGUI:’Rcmdr’Plug-in GUI for Biclustering (2016)
Kamburov, A., Stelzl, U., Lehrach, H. & Herwig, R. The ConsensusPathDB interaction database: 2013 update. Nucl. Acids Res. 41, D793-800 (2012).
pubmed: 23143270 pmcid: 3531102 doi: 10.1093/nar/gks1055
Dimitrakopoulos, C. et al. Network-based integration of multi-omics data for prioritizing cancer genes. Bioinformatics 34, 2441–2448 (2018).
pubmed: 29547932 pmcid: 6041755 doi: 10.1093/bioinformatics/bty148
Kassambara, A., Kosinski, M. & Biecek, P. Survminer: drawing survival curves using’ggplot2’. R package version 0.3 1 (2017).
Kolde R, Kolde MR. Package ‘pheatmap’. R package, 1 (2015)

Auteurs

Archana Bhardwaj (A)

GIGA-R Centre, BIO3 - Medical Genomics, University of Liège, Avenue de L'Hôpital, 11, 4000, Liège, Belgium. a.bhardwaj@uliege.be.

Claire Josse (C)

Laboratory of Human Genetics, GIGA Research, University Hospital (CHU), Liège, Belgium.
Medical Oncology Department, CHU Liège, Liège, Belgium.

Daniel Van Daele (D)

Department of Gastro-Enterology, University Hospital (CHU), Liège, Belgium.

Christophe Poulet (C)

Laboratory of Human Genetics, GIGA Research, University Hospital (CHU), Liège, Belgium.
Laboratory of Rheumatology, GIGA-R, University Hospital (CHULiege), Liège, Belgium.

Marcela Chavez (M)

Department of Medicine, Division of Hematology, University Hospital (CHU), Liège, Belgium.

Ingrid Struman (I)

GIGA-R Centre, Laboratory of Molecular Angiogenesis, University of Liège, Liège, Belgium.

Kristel Van Steen (K)

GIGA-R Centre, BIO3 - Medical Genomics, University of Liège, Avenue de L'Hôpital, 11, 4000, Liège, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH